Research programme: chymase inhibitors - Bayer/Celera Genomics

Drug Profile

Research programme: chymase inhibitors - Bayer/Celera Genomics

Alternative Names: Chymase inhibitors research programme - Bayer/Celera Genomics

Latest Information Update: 10 Dec 1998

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celera Genomics Group
  • Developer Bayer; Celera Genomics Group
  • Class
  • Mechanism of Action Chymase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Heart failure; Respiratory tract disorders; Rheumatoid arthritis

Most Recent Events

  • 10 Dec 1998 Discontinued-Preclinical for Heart failure in USA (Unknown route)
  • 10 Dec 1998 Discontinued-Preclinical for Respiratory tract disorders in USA (Unknown route)
  • 10 Dec 1998 Discontinued-Preclinical for Rheumatoid arthritis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top